A5066518344- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Pituitary Gland Disorders and Treatments
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Uterine Myomas and Treatments
- Glioma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Thyroid Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Vehicle emissions and performance
- Head and Neck Cancer Studies
- Adrenal and Paraganglionic Tumors
- Cancer Diagnosis and Treatment
- Air Quality and Health Impacts
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Antiplatelet Therapy and Cardiovascular Diseases
Karolinska University Hospital
2017-2025
Karolinska Institutet
2017-2024
Aristotle University of Thessaloniki
2023-2024
The Radiosurgery Society
2023
Sophiahemmet Hospital
2018
Hygeia Hospital
2017
Uppsala University
2013-2014
Metaxa Hospital
2006-2011
General-Maternity District Hospital Helena Venizelou
2005
IntroductionWe analysed patients with advanced non–small cell lung cancer (NSCLC) who were treated immune-checkpoint inhibitors (ICIs) to address the effect of timeline and reason for corticosteroid administration on survival outcomes.MethodsWe retrospectively collected clinical data non-oncogenic driven, NSCLC ICIs at Karolinska University Hospital, including steroid administration. Steroid was defined as > 10 mg prednisolone equivalent ≥10 days. We subcategorized based aetiology into three...
Non-small cell lung cancer (NSCLC) with brain metastases (BM) is a challenging clinical issue poor prognosis. No data exist regarding extensive genetic analysis of cerebrospinal fluid (CSF) and its correlation to associated tumor compartments.We designed study across multiple NSCLC patients matched material from four compartments; primary tumor, BM, plasma CSF. We performed enrichment-based targeted next-generation sequencing ctDNA exosomal RNA in CSF compared the outcome solid...
Non-small cell lung cancer (NSCLC) harboring activating mutations in the gene encoding epidermal growth factor receptor (EGFR) is amenable for targeted therapy with tyrosine kinase inhibitors (TKIs). Eventually, resistance to TKI-therapy occurs resulting disease progression. A substantial fraction of mechanisms unknown and may involve alterations RNA or protein landscape. MicroRNAs (miRNAs) have been frequently suggested play roles various forms including NSCLC. However, a role miRNAs...
Chemoradiotherapy is standard treatment for limited stage (LS) small-cell lung cancer (SCLC). A majority of patients relapse and there a need better treatment. We investigated whether twice-daily thoracic radiotherapy (TRT) 60 Gy/40 fractions improve survival compared with the established schedule 45 Gy/30 fractions. Here we report final data long-term toxicity. Randomised, open-label, phase II trial. Eligible had PS 0-2, were ≥18 years, underwent FDG-PET/CT brain MRI staging randomised 1:1...
2024 Background: Stereotactic radiosurgery (SRS) is a standard local treatment for brain metastases (BM), but it may result in recurrence (LR) or radionecrosis (RN). This study evaluates irradiated tumor volume as predictor of LR and RN SRS-treated lung cancer patients with BM. Methods: We retrospectively analyzed 431 BM who underwent SRS at Karolinska University Hospital, Sweden, (2009-2020), encompassing all-comers from the Stockholm region. Associations among risks RN, symptomatic well 6...
LBA8005 Background: A majority of patients with LS SCLC relapse after potentially curative CRT and better treatment is needed. Immunotherapy prolongs survival in extensive stage non-small cell lung cancer. We investigated whether atezolizumab (“atezo”) SCLC. Methods: Patients PS 0-2 non-progression (PD) platinum/etoposide chemotherapy concurrent twice-daily thoracic radiotherapy (TRT) 45 Gy/30 or 60 Gy/40 fractions were randomized 1:1 to observation atezo 1200 mg Q3W for 1 year, until PD...
Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. Therefore, we evaluated the three-drug combination paclitaxel-ifosfamide-cisplatin (TIP).Systemic chemotherapy-naive patients advanced metastatic/relapsed World Health Organization (WHO) performance status (PS) 0-2 were eligible. TIP chemotherapy doses paclitaxel 175 mg m(-2) on day 1, ifosfamide 2.5 g days 1+2, cisplatin 40 prophylactic granulocyte-colony...
The prognosis of high-grade glioma patients is poor, and the tumors are characterized by resistance to therapy. aims this study were analyze prognostic value expression protein tyrosine phosphatase non-receptor type 6 (PTPN6, also referred as SHP1) in patients, epigenetic regulation PTPN6, role its chemotherapy glioma-derived cells. PTPN6 was analyzed with immunohistochemistry 89 patients. Correlation between overall survival Kaplan-Meier univariate analysis Cox regression multivariate...
Caloric restriction in animals is an effective way to reduce carcinogenesis. Anorexia nervosa (AN) considered a model of extreme caloric humans. The aim our study was assess cancer incidence and mortality women with AN. A total 6,009 at least one inpatient treatment for AN during the period 1973-2003 were included study. Standardized ratios (SIR) standardized (SMR) calculated. Overall, there no statistically significant difference compared general population. At or borderline level, higher...
Platinum-based chemotherapy with cetuximab is the standard of care for relapsed or metastatic squamous cell carcinoma head and neck (SCCHN). The aim this trial was to investigate whether paclitaxel/carboplatin can achieve similar progression-free survival (PFS) 5-FU/platinum-based chemotherapy. Standard treatment SCCHN related severe toxicity new, less toxic regimens are needed.In multicentre, randomized, controlled, phase 2 trial, 85 patients were randomized in a 1:1 ratio 5-FU/cisplatin...
There is lack of data addressing the intracranial (IC) efficacy immune checkpoint inhibitors (ICIs) on brain metastases (BM) in non-small cell lung cancer (NSCLC). This patient category underrepresented randomized clinical trials. We retrospectively collected patients with non-oncogenic driven NSCLC BM who were treated ICIs at two medical oncology institutes Sweden and Greece from 2016 to 2019. IC was assessed had not received local treatment for less than three months prior initiation...
BackgroundDissemination of non–small-cell lung cancer (NSCLC) in the central nervous system is a frequent and challenging clinical problem. Systemic or local therapies rarely prolong survival have modest activity regarding control. Alterations gene expression brain metastasis versus primary tumour may increase aggressiveness impair therapeutic efforts.MethodsWe identified 25 patients with surgically removed NSCLC metastases two different patient cohorts. For 13 these patients, samples were...
6032 Background: Platinum-based chemotherapy with cetuximab is the standard of care for relapsed or metastatic squamous cell carcinoma head and neck (SCCHN). The aim this trial was to investigate whether paclitaxel/carboplatin can achieve similar progression free survival (PFS) less toxicity compared 5-FU/platinum based chemotherapy. Methods: In multicentre, randomised, controlled, phase 2 trial, 85 patients SCCHN were randomised in a 1:1 ratio 5-FU/cisplatin carboplatin (arm A, n = 42),...
There is a paucity of biomarkers for the prediction intracranial (IC) outcome in immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM). We identified 280 NSCLC pts treated ICIs at Karolinska University Hospital, Sweden, and Hospital Heraklion, Greece. The inclusion criteria response assessment were (BM) prior to ICI administration, radiological evaluation CT or MRI IC assessment, PD-1/PD-L1 inhibitors as monotherapy, no local...
8512 Background: Concurrent chemotherapy and TRT is standard treatment of LS SCLC. BID 45 Gy/30 fractions the most recommended schedule. Trials report 5-year survival rates up to 36%, illustrating that some are cured but also need for better treatment. Many failures due relapses within fields, it has been proposed higher doses might improve local control consequently survival. However, high-dose once-daily (QD) 66-70 Gy do not prolong We investigated whether 60 Gy/40 was tolerable improved...